Pharmaceutically Produced Cannabidiol
Our pharmaceutically produced ultra-pure cannabidiol formulation has been developed specifically for medical purposes. It is free from the psychotropic effects of THC and is produced using controlled processes in approved current Good Manufacturing Practices (cGMP) pharmaceutical facilities. This allows for consistent quality, purity, and stability from batch to batch, resulting in a THC-free (<10 ppm) cannabidiol oil – ideal for patients who should not take THC.
CardiolRx™ is an ultra pure, high concentration cannabidiol oral formulation being developed for the treatment of acute inflammatory heart disease. It is pharmaceutically produced under cGMP to meet the highest standards for product purity, consistency, and stability, and is THC free (<10 ppm).
Cardiol has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application to conduct a Phase II/III clinical trial investigating the efficacy and safety of CardiolRx in the treatment of hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease.
Cardiol has conducted a Phase I safety and pharmacokinetic study of CardiolRx and is planning an international, multi-center Phase II study to investigate the therapeutic effects of CardiolRx on myocardial recovery in patients with acute myocarditis, the leading cause of sudden cardiac death in people under 35 years of age.
The Company is also developing a subcutaneous formulation of CardiolRx to achieve higher bioavailability than an oral formulation for the treatment of chronic heart failure. Heart failure affects over six million people in North America and remains a leading cause of death and hospitalization with associated U.S. healthcare costs exceeding $30 billion annually.